Baron Capital, an investment management firm, released its Q2 2026 investor letter for the Baron Focused Growth Fund. The fund achieved a 13.26% gain in the second quarter, although it trailed the Russell 2500 Growth Index's 24.02% return. This underperformance was primarily due to lingering worries about the influence of artificial intelligence on the fund's portfolio companies and a lower-than-average exposure to AI infrastructure. While the IPO of SpaceX provided some uplift, the fund's core companies continue to demonstrate strong revenue expansion and improving profit margins, driven by enhanced customer engagement and product offerings. Many stocks within the portfolio are currently considered undervalued, and companies are initiating accelerated share repurchase programs, which is boosting investor confidence. The fund's prospects are viewed as favorable, supported by positive market trends and robust financial health, with inflation and interest rates anticipated to remain stable. Over the past 3, 5, and 10 years, the fund has consistently surpassed its benchmark, delivering substantial excess returns with reduced market risk, a testament to its research-driven investment philosophy. The fund remains dedicated to a long-term investment approach in growth-oriented businesses, maintaining a balanced portfolio to mitigate risks and potentially amplify returns.
Within its Q2 2026 investor letter, the Baron Focused Growth Fund specifically highlighted IDEXX Laboratories, Inc. (IDXX). IDEXX Laboratories, Inc. is a prominent entity involved in the development, manufacturing, and distribution of products tailored for the companion animal veterinary, livestock and poultry, dairy, and water testing sectors. As of August 19, 2026, IDEXX Laboratories, Inc. (IDXX) concluded trading at $562.20 per share, commanding a market capitalization of $44.29 billion. Over the preceding month, IDEXX Laboratories, Inc. (IDXX) recorded a 4.23% return, though its shares experienced an 11.19% decline over the past 52 weeks. Baron Focused Growth Fund articulated its rationale for holding IDEXX, stating: "In Health Care, we invest in competitively advantaged companies that are leaders in their industries such as IDEXX Laboratories, Inc. (IDXX), the leading provider of diagnostics to the veterinary industry and who is benefiting from the increase in pets that people acquired during the COVID pandemic, especially as these pets age. The Fund is further diversified by investments in businesses at different stages of growth and development."
While IDEXX Laboratories, Inc. (IDXX) is not featured among the most popular stocks held by hedge funds, with 62 hedge fund portfolios holding the stock at the end of the first quarter (an increase from 58 in the previous quarter), the fund acknowledges its potential as an investment. However, it also suggests that certain AI stocks may offer greater upside potential with reduced downside risk. For investors seeking an undervalued AI stock that could significantly benefit from future economic shifts, alternative options are available.
